Corcept Therapeutics Inc Financials
Corcept Therapeutics Inc (CORT) reported $761.4M in revenue for fiscal year 2025, up 12.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Corcept runs a 98.3% gross-margin, capital-light model, but expanding R&D and SG&A now consume most new revenue.
The important shift is not in product economics: from FY2023 to FY2025, revenue climbed from$482.4M to$761.4M while gross margin stayed near98% , yet operating margin fell from22.2% to5.9% because SG&A and R&D absorbed the scale benefit. Net income of$99.7M therefore looks healthier than operating income alone would suggest, because it was helped by a-$33.2M tax line rather than stronger core operations.
Cash conversion stayed better than the operating margin implies: FY2025 operating cash flow was
The balance sheet is supporting that spending choice internally, not through lenders: FY2025 liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Corcept Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Corcept Therapeutics Inc has an operating margin of 5.9%, meaning the company retains $6 of operating profit per $100 of revenue. This strong profitability earns a score of 72/100, reflecting efficient cost management and pricing power. This is down from 20.3% the prior year.
Corcept Therapeutics Inc's revenue grew 12.8% year-over-year to $761.4M, a solid pace of expansion. This earns a growth score of 86/100.
Corcept Therapeutics Inc carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 69/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.92, Corcept Therapeutics Inc holds $2.92 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.
Corcept Therapeutics Inc converts 18.6% of revenue into free cash flow ($141.8M). This strong cash generation earns a score of 90/100.
Corcept Therapeutics Inc earns a strong 15.4% return on equity (ROE), meaning it generates $15 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 73/100. This is down from 20.8% the prior year.
Corcept Therapeutics Inc scores 44.95, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($13.3B) relative to total liabilities ($188.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Corcept Therapeutics Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Corcept Therapeutics Inc generates $1.42 in operating cash flow ($142.0M OCF vs $99.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Corcept Therapeutics Inc generated $761.4M in revenue in fiscal year 2025. This represents an increase of 12.8% from the prior year.
Corcept Therapeutics Inc's EBITDA was $45.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 66.6% from the prior year.
Corcept Therapeutics Inc reported $99.7M in net income in fiscal year 2025. This represents a decrease of 29.4% from the prior year.
Corcept Therapeutics Inc earned $0.82 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.3% from the prior year.
Cash & Balance Sheet
Corcept Therapeutics Inc generated $141.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.7% from the prior year.
Corcept Therapeutics Inc held $120.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Corcept Therapeutics Inc's gross margin was 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.
Corcept Therapeutics Inc's operating margin was 5.9% in fiscal year 2025, reflecting core business profitability. This is down 14.4 percentage points from the prior year.
Corcept Therapeutics Inc's net profit margin was 13.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.8 percentage points from the prior year.
Corcept Therapeutics Inc's ROE was 15.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.4 percentage points from the prior year.
Capital Allocation
Corcept Therapeutics Inc invested $254.9M in research and development in fiscal year 2025. This represents an increase of 3.2% from the prior year.
Corcept Therapeutics Inc spent $172.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1003.9% from the prior year.
Corcept Therapeutics Inc invested $211K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.3% from the prior year.
CORT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $830.8M | $761.4M+12.8% | $675.0M+39.9% | $482.4M+20.0% | $401.9M+9.8% | $366.0M+3.4% | $353.9M+15.5% | $306.5M+22.0% | $251.2M+57.8% | $159.2M+95.8% | $81.3M+61.7% | $50.3M+89.4% | $26.6M+156.4% | $10.4M+213.2% | $3.3M | N/A |
| Cost of Revenue | $14.1M | $13.0M+19.3% | $10.9M+67.9% | $6.5M+20.4% | $5.4M+2.0% | $5.3M-5.4% | $5.6M+1.4% | $5.5M+5.5% | $5.2M+46.7% | $3.6M+72.7% | $2.1M+51.2% | $1.4M+54.3% | $882K+516.8% | $143K+57.1% | $91K | N/A |
| Gross Profit | $816.7M | $748.4M+12.7% | $664.2M+39.6% | $475.9M+20.0% | $396.5M+9.9% | $360.7M+3.6% | $348.3M+15.7% | $301.0M+22.3% | $246.0M+58.1% | $155.6M+96.4% | $79.3M+62.0% | $48.9M+90.6% | $25.7M+151.3% | $10.2M+217.6% | $3.2M | N/A |
| R&D Expenses | $253.9M | $254.9M+3.2% | $246.9M+33.9% | $184.4M+40.7% | $131.0M+15.0% | $113.9M-0.8% | $114.8M+28.9% | $89.0M+18.3% | $75.2M+86.4% | $40.4M+69.3% | $23.8M+54.6% | $15.4M-16.1% | $18.4M-10.2% | $20.5M+45.4% | $14.1M-33.0% | $21.0M |
| SG&A Expenses | $556.5M | $448.7M+60.1% | $280.3M+52.1% | $184.3M+20.6% | $152.8M+24.9% | $122.4M+16.2% | $105.3M+4.9% | $100.4M+23.5% | $81.3M+30.2% | $62.4M+38.0% | $45.2M+22.4% | $36.9M+5.8% | $34.9M+11.8% | $31.2M+22.9% | $25.4M+124.3% | $11.3M |
| Operating Income | $6.4M | $44.8M-67.3% | $137.0M+27.7% | $107.3M-4.8% | $112.6M-9.5% | $124.5M-2.9% | $128.2M+14.9% | $111.6M+24.7% | $89.5M+69.3% | $52.9M+419.3% | $10.2M+395.6% | -$3.4M+87.5% | -$27.6M+33.4% | -$41.5M-14.4% | -$36.3M-12.2% | -$32.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $2.0M-31.2% | $3.0M-21.2% | $3.8M-16.6% | $4.5M+165.6% | $1.7M+6700.0% | $25K |
| Income Tax | -$28.8M | -$33.2M-263.6% | $20.3M+10.1% | $18.4M+24.7% | $14.8M+18.2% | $12.5M-51.2% | $25.6M+13.8% | $22.5M+34.4% | $16.7M+121.9% | -$76.3M | $0 | $0 | $0 | N/A | N/A | N/A |
| Net Income | $55.2M | $99.7M-29.4% | $141.2M+33.0% | $106.1M+4.7% | $101.4M-9.9% | $112.5M+6.1% | $106.0M+12.6% | $94.2M+24.9% | $75.4M-41.6% | $129.1M+1486.3% | $8.1M+227.0% | -$6.4M+79.6% | -$31.4M+31.8% | -$46.0M-20.9% | -$38.0M-17.6% | -$32.4M |
| EPS (Diluted) | — | $0.82-33.3% | $1.23+30.9% | $0.94+8.0% | $0.87-2.2% | $0.89+4.7% | $0.85+10.4% | $0.77+28.3% | $0.60-42.3% | $1.04+1385.7% | $0.07+216.7% | -$0.06 | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CORT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $836.7M-0.5% | $840.6M+35.2% | $621.5M+6.5% | $583.4M+37.7% | $423.8M-25.9% | $571.7M+38.7% | $412.3M+32.3% | $311.7M+41.3% | $220.5M+220.8% | $68.8M+32.5% | $51.9M+49.9% | $34.6M-45.1% | $63.1M-36.4% | $99.2M+149.0% | $39.8M |
| Current Assets | $485.5M+2.9% | $471.6M+2.8% | $458.6M-8.1% | $499.3M+87.4% | $266.5M-44.3% | $478.5M+55.7% | $307.4M+29.8% | $236.8M+90.7% | $124.2M+89.0% | $65.7M+34.1% | $49.0M+62.0% | $30.2M-48.2% | $58.3M-38.7% | $95.1M+139.0% | $39.8M |
| Cash & Equivalents | $120.5M-5.6% | $127.7M-5.8% | $135.6M+104.4% | $66.3M-14.5% | $77.6M+1.9% | $76.2M+143.7% | $31.3M-24.9% | $41.6M+34.0% | $31.1M-39.7% | $51.5M+27.5% | $40.4M+66.8% | $24.2M-55.8% | $54.9M-41.0% | $93.0M+134.7% | $39.6M |
| Inventory | $12.9M+3.7% | $12.4M+60.6% | $7.7M+26.7% | $6.1M+22.3% | $5.0M+1.6% | $4.9M-9.5% | $5.4M+14.6% | $4.7M+3.4% | $4.6M+96.5% | $2.3M+38.5% | $1.7M+39.4% | $1.2M+10.1% | $1.1M+28.5% | $853K | N/A |
| Accounts Receivable | $59.8M+10.8% | $54.0M+31.3% | $41.1M+32.4% | $31.1M+12.4% | $27.6M+5.4% | $26.2M+31.5% | $19.9M+13.3% | $17.6M+15.0% | $15.3M+55.2% | $9.9M+58.5% | $6.2M+86.6% | $3.3M+133.5% | $1.4M+156.4% | $557K | N/A |
| Total Liabilities | $188.8M+17.3% | $161.0M+40.2% | $114.8M+40.7% | $81.6M+70.2% | $48.0M-0.9% | $48.4M+17.7% | $41.1M+14.8% | $35.8M+21.1% | $29.6M+8.0% | $27.4M-18.1% | $33.4M-12.1% | $38.0M-9.6% | $42.1M+12.5% | $37.4M+643.9% | $5.0M |
| Current Liabilities | $166.1M+18.0% | $140.8M+34.7% | $104.5M+44.2% | $72.5M+52.5% | $47.5M+0.1% | $47.5M+22.3% | $38.8M+9.2% | $35.6M+20.3% | $29.6M+8.0% | $27.4M+31.1% | $20.9M+54.0% | $13.6M+6.4% | $12.7M+52.4% | $8.4M+66.3% | $5.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $12.5M-48.8% | $24.5M-16.6% | $29.3M+1.0% | $29.0M | N/A |
| Total Equity | $647.8M-4.7% | $679.6M+34.1% | $506.7M+1.0% | $501.8M+33.5% | $375.8M-28.2% | $523.3M+41.0% | $371.2M+34.5% | $275.9M+44.5% | $191.0M+361.5% | $41.4M+123.7% | $18.5M+646.0% | -$3.4M-116.1% | $21.0M-66.0% | $61.8M+77.5% | $34.8M |
| Retained Earnings | $643.4M+18.3% | $543.7M+35.1% | $402.5M+35.8% | $296.4M+52.0% | $195.0M+136.5% | $82.5M+450.1% | -$23.6M+80.0% | -$117.7M+39.0% | -$193.1M+40.1% | -$322.3M+2.5% | -$330.4M-2.0% | -$324.0M-10.7% | -$292.6M-18.7% | -$246.6M-18.2% | -$208.6M |
Not reported in any period shown, so not listed: Goodwill.
CORT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $109.7M | $142.0M-28.4% | $198.3M+56.5% | $126.7M+5.3% | $120.3M-28.3% | $167.9M+10.5% | $152.0M+11.6% | $136.1M+17.7% | $115.7M+89.8% | $60.9M+231.3% | $18.4M+487.6% | $3.1M+111.4% | -$27.4M+26.1% | -$37.1M-2.9% | -$36.0M-31.5% | -$27.4M |
| Capital Expenditures | $2.8M | $211K-90.3% | $2.2M+1462.6% | $139K-66.3% | $413K-11.9% | $469K-62.1% | $1.2M+13.8% | $1.1M+265.1% | $298K-28.9% | $419K+116.0% | $194K+1041.2% | $17K-90.2% | $174K+37.0% | $127K-15.9% | $151K+504.0% | $25K |
| Free Cash Flow | $106.9M | $141.8M-27.7% | $196.1M+55.0% | $126.5M+5.5% | $119.9M-28.4% | $167.4M+11.1% | $150.7M+11.6% | $135.0M+17.0% | $115.4M+90.6% | $60.5M+232.6% | $18.2M+484.5% | $3.1M+111.3% | -$27.6M+25.9% | -$37.2M-2.8% | -$36.2M-31.9% | -$27.4M |
| Investing Cash Flow | -$21.9M | $69.8M+139.3% | -$177.6M-295.4% | $90.9M+179.5% | -$114.3M-184.0% | $136.1M+214.1% | -$119.3M-1.2% | -$117.8M-29.8% | -$90.8M-23.6% | -$73.5M-37763.9% | -$194K | N/A | N/A | -$127K+15.9% | -$151K-504.0% | -$25K |
| Financing Cash Flow | -$78.9M | -$220.4M-677.3% | -$28.3M+80.9% | -$148.7M-760.5% | -$17.3M+94.3% | -$302.6M-2577.4% | $12.2M+142.6% | -$28.6M-99.8% | -$14.3M-80.2% | -$8.0M-12.1% | -$7.1M | N/A | N/A | -$970K-101.1% | $89.6M+110.8% | $42.5M |
| Share Buybacks | $42.5M | $172.9M+1003.9% | $15.7M | $0 | $0 | N/A | $9.9M-67.9% | $31.0M+30.9% | $23.7M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CORT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3%-0.1pp | 98.4%-0.3pp | 98.7%0.0pp | 98.7%+0.1pp | 98.6%+0.1pp | 98.4%+0.2pp | 98.2%+0.3pp | 97.9%+0.1pp | 97.8%+0.3pp | 97.5%+0.2pp | 97.3%+0.6pp | 96.7%-1.9pp | 98.6%+1.4pp | 97.3% | N/A |
| Operating Margin | 5.9%-14.4pp | 20.3%-1.9pp | 22.2%-5.8pp | 28.0%-6.0pp | 34.0%-2.2pp | 36.2%-0.2pp | 36.4%+0.8pp | 35.6%+2.4pp | 33.2%+20.7pp | 12.5%+19.4pp | -6.9% | -104.0% | -400.7% | -1096.8% | N/A |
| Net Margin | 13.1%-7.8pp | 20.9%-1.1pp | 22.0%-3.2pp | 25.2%-5.5pp | 30.7%+0.8pp | 30.0%-0.8pp | 30.7%+0.7pp | 30.0%-51.1pp | 81.1%+71.1pp | 10.0%+22.8pp | -12.7% | -118.2% | -444.3% | -1150.5% | N/A |
| Return on Equity | 15.4%-5.4pp | 20.8%-0.2pp | 20.9%+0.7pp | 20.2%-9.7pp | 29.9%+9.7pp | 20.3%-5.1pp | 25.4%-2.0pp | 27.3%-40.3pp | 67.6%+47.9pp | 19.7%+54.3pp | -34.6% | N/A | -218.9%-157.3pp | -61.6%+31.4pp | -93.0% |
| Return on Assets | 11.9%-4.9pp | 16.8%-0.3pp | 17.1%-0.3pp | 17.4%-9.2pp | 26.6%+8.0pp | 18.5%-4.3pp | 22.8%-1.4pp | 24.2%-34.4pp | 58.6%+46.7pp | 11.8%+24.2pp | -12.3%+78.3pp | -90.6%-17.7pp | -72.9%-34.6pp | -38.4%+42.9pp | -81.2% |
| Current Ratio | 2.92-0.4x | 3.35-1.0x | 4.39-2.5x | 6.89+1.3x | 5.60-4.5x | 10.07+2.2x | 7.91+1.3x | 6.66+2.5x | 4.20+1.8x | 2.40+0.1x | 2.35+0.1x | 2.23-2.3x | 4.58-6.8x | 11.37+3.5x | 7.91 |
| Debt-to-Equity | 0.29+0.1x | 0.240.0x | 0.23+0.1x | 0.160.0x | 0.130.0x | 0.090.0x | 0.110.0x | 0.13+0.1x | 0.000.0x | 0.00-0.7x | 0.68 | N/A | 1.40+0.9x | 0.47+0.3x | 0.14 |
| FCF Margin | 18.6%-10.4pp | 29.0%+2.8pp | 26.2%-3.6pp | 29.8%-15.9pp | 45.8%+3.2pp | 42.6%-1.5pp | 44.1%-1.9pp | 45.9%+7.9pp | 38.0%+15.6pp | 22.4%+16.2pp | 6.2% | -103.8% | -359.0% | -1093.8% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Corcept Therapeutics Inc Ranks
Frequently Asked Questions
What is Corcept Therapeutics Inc's annual revenue?
Corcept Therapeutics Inc (CORT) reported $761.4M in total revenue for fiscal year 2025. This represents a 12.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Corcept Therapeutics Inc's revenue growing?
Corcept Therapeutics Inc (CORT) revenue grew by 12.8% year-over-year, from $675.0M to $761.4M in fiscal year 2025.
Is Corcept Therapeutics Inc profitable?
Yes, Corcept Therapeutics Inc (CORT) reported a net income of $99.7M in fiscal year 2025, with a net profit margin of 13.1%.
What is Corcept Therapeutics Inc's EBITDA?
Corcept Therapeutics Inc (CORT) had EBITDA of $45.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Corcept Therapeutics Inc's gross margin?
Corcept Therapeutics Inc (CORT) had a gross margin of 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Corcept Therapeutics Inc's operating margin?
Corcept Therapeutics Inc (CORT) had an operating margin of 5.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Corcept Therapeutics Inc's net profit margin?
Corcept Therapeutics Inc (CORT) had a net profit margin of 13.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Corcept Therapeutics Inc's return on equity (ROE)?
Corcept Therapeutics Inc (CORT) has a return on equity of 15.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Corcept Therapeutics Inc's free cash flow?
Corcept Therapeutics Inc (CORT) generated $141.8M in free cash flow during fiscal year 2025. This represents a -27.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Corcept Therapeutics Inc's operating cash flow?
Corcept Therapeutics Inc (CORT) generated $142.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Corcept Therapeutics Inc's total assets?
Corcept Therapeutics Inc (CORT) had $836.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Corcept Therapeutics Inc's capital expenditures?
Corcept Therapeutics Inc (CORT) invested $211K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Corcept Therapeutics Inc spend on research and development?
Corcept Therapeutics Inc (CORT) invested $254.9M in research and development during fiscal year 2025.
What is Corcept Therapeutics Inc's current ratio?
Corcept Therapeutics Inc (CORT) had a current ratio of 2.92 as of fiscal year 2025, which is generally considered healthy.
What is Corcept Therapeutics Inc's debt-to-equity ratio?
Corcept Therapeutics Inc (CORT) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Corcept Therapeutics Inc's return on assets (ROA)?
Corcept Therapeutics Inc (CORT) had a return on assets of 11.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Corcept Therapeutics Inc's Altman Z-Score?
Corcept Therapeutics Inc (CORT) has an Altman Z-Score of 44.95, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Corcept Therapeutics Inc's Piotroski F-Score?
Corcept Therapeutics Inc (CORT) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Corcept Therapeutics Inc's earnings high quality?
Corcept Therapeutics Inc (CORT) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Corcept Therapeutics Inc?
Corcept Therapeutics Inc (CORT) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.